The tweet was deleted by the author.
But we saved everything 🙂.
Patrick Collison, CEO of Stripe, recently highlighted the surprisingly small proportion of the US GDP spent on pharmaceuticals—approximately 1.6 percent.
Collison emphasized that this figure represents exceptional value for money when one considers the welfare gains achieved through pharmaceutical consumption. Moreover, he noted the significant extent to which the US pharmaceutical market subsidizes the rest of the world.
His comments bring attention to a critical analysis of how healthcare and pharmaceutical spending contribute to economic and social well-being within the United States.
Collison’s perspective on healthcare spending intersects with his broader commentary on the economics of innovation—an outlook also reflected when he humorously critiqued investor warning folklore and the ways traditional financial assumptions shape industry thinking. His ongoing commitment to fostering global progress in technology, as demonstrated by his efforts to bring a major digital project to Europe, underscores the interconnectedness of economic policies, investment attitudes, and advancements in health and welfare.